AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data. Now, Vyalev (foscarbidopa ...

The global enteral formula market is on a robust upward trajectory, forecast to nearly double in value from USD 8.5 billion ...

June 28, 2019 Jejunostomy tube manufacturer draws FDA warning letter June 26, 2019 FDA offers guidance on data for prostate ablation devices MRI as safe as cardiac catheterization for coronary disease ...